A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|15|8|665-683

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.15, Iss.8, 2015-01, pp. : 665-683

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel Targeted Therapies to Overcome Trastuzumab Resistance in HER2- Overexpressing Metastatic Breast Cancer

By  

Current Drug Targets, Vol. 14, Iss. 8, 2013-07 ,pp. : 889-898

Bentham Science Publishers

Access to resources Recommend Favorite

Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer

By  

Current Cancer Drug Targets, Vol. 9, Iss. 2, 2009-03 ,pp. : 148-162

Bentham Science Publishers

Access to resources Recommend Favorite

Trastuzumab: A Review of its Use in the Treatment of Metastatic Breast Cancer Overexpressing HER2

By McKeage K.   Perry C.M.  

Drugs, Vol. 62, Iss. 1, 2002-01 ,pp. : 209-243

Adis International

Access to resources Recommend Favorite

Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients

By Al-Dasooqi Noor   Bowen Joanne   Gibson Rachel   Sullivan Thomas   Lees Jude   Keefe Dorothy  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 173-178

Springer Publishing Company

Access to resources Recommend Favorite

Lapatinib: A Review of its Use in the Treatment of HER2-Overexpressing, Trastuzumab-Refractory, Advanced or Metastatic Breast Cancer

By Frampton James E.  

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2125-2148

Adis International

Access to resources Recommend Favorite